While several over-the-counter and prescription medications can treat migraine, not all are good at easing symptoms like head pain, nausea, vomiting, and sensitivity to light that can last a few hours ...
Peter L. Salgo, MD: There are some newly approved classes of agents out there—human monoclonal antibodies, MAB treatments, that block the calcitonin gene-related peptide, CGRP. What is their mechanism ...
Since first introduced, anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies and CGRP antagonists (gepants) have had a transformative impact on migraine management, both preventive and ...
Use of calcitonin gene-related peptide (CGRP) inhibitors to treat migraine is associated with a reduced risk for glaucoma, new research showed. In a multinational retrospective study of nearly 74,000 ...
S ince 2018, when the U.S. Food and Drug Administration (FDA) approved the first calcitonin gene-related peptide (CGRP) antagonist for migraine disease, this class of drugs has revolutionized the ...
Meloxicam/Rizatriptan Effective in Migraine Patients With Inadequate Response to Oral CGRP Inhibitor
Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...
Migraine patients taking CGRP inhibitors had a 25% lower risk of developing glaucoma within 3 years. Only monoclonal antibody CGRP inhibitors, not CGRP receptor antagonists, were linked with reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results